In this phase III randomized study, 1-year pembrolizumab showed significant DFS improve in all-comers populations of resected stage IB (≥4 cm)-IIIA NSCLC (7th TNM edition) (median 53.6 vs 42.0 months; HR 0.76, 95% CI 0.63-0.91, p = 0.0014) but not in PD-L1 high subgroup (however with median not reached in either arm) (21). Here, CD274 is linked to non-small cell lung carcinoma.